Table 1.
Patient characteristics of 823 patients with benign histology after VASB of clustered calcifications.
| Number of patients (n) | Percentage (%) | Mean ± std | |
|---|---|---|---|
| Age at first presentation, in years | 823 | 55.7 ± 10.3 | |
| Referral | |||
| National screening program | 416 | 50.5 | |
| General practitioner | 188 | 22.8 | |
| Follow-up | 215 | 26.1 | |
| Biopsy for other hospital | 4 | 0.5 | |
| In case of referral by follow-up, specification of reason for follow-up | |||
| History of breast cancer | 96 | 11.7 | |
| History or analysis of other malignancy than breast cancer | 7 | 0.9 | |
| Family history of breast cancer | 42 | 5.1 | |
| Benign breast lesion | 65 | 7.9 | |
| Hormonal drug therapy | 4 | 0.5 | |
| Preoperative screening | 1 | 0.1 | |
| History of breast cancer | |||
| No | 719 | 87.4 | |
| Yes | 97 | 11.8 | |
| Missing | 7 | 0.9 | |
| In case of history of breast cancer, side of cancer compared to calcifications | |||
| Ipsilateral | 41 | 5.0 | |
| Contralateral | 56 | 6.8 | |
| BI-RADS classification at the moment of VASB | |||
| BI-RADS 3 | 166 | 20.2 | |
| BI-RADS 4 | 649 | 78.9 | |
| BI-RADS 5 | 1 | 0.2 | |
| Missing | 6 | 0.7 | |
| Breast with clustered calcifications | |||
| Left | 431 | 52.4 | |
| Right | 392 | 47.6 | |
| Histopathologic findings | |||
| Breast tissue without abnormalities | 223 | 27.1 | |
| Mastopathy | 287 | 34.9 | |
| Fibroadenoma | 73 | 8.9 | |
| Fibrosis/fibrocystic breast changes | 75 | 9.1 | |
| (Sclerosing) Adenosis or sclerosis | 34 | 4.1 | |
| Hyperplasia | 27 | 3.3 | |
| Apocrine metaplasia | 19 | 2.3 | |
| Inflammation/necrosis | 19 | 2.3 | |
| Epitheliosis or epithelial proliferation | 11 | 1.3 | |
| Lactational changes | 3 | 0.4 | |
| Combination of different benign pathologic findings | 23 | 2.8 | |
| In case of a combination of different benign pathologic findings, specification | |||
| Fibroadenoma + adenosis | 1 | 0.1 | |
| Fibroadenoma + fibrosis | 1 | 0.1 | |
| Fibroadenoma + mastopathy | 12 | 1.5 | |
| Mastopathya + mucocele like lesion | 1 | 0.1 | |
| Mastopathy + inflammation | 3 | 0.4 | |
| Mastopathy + PASHb | 1 | 0.1 | |
| Inflammation + epitheliosis/fibrosis | 2 | 0.2 | |
| Radiation therapy induced changes + fibrosis + necrosis | 1 | 0.1 | |
| Synchronous contralateral breast malignancy | |||
| No | 779 | 97.1 | |
| Yes | 24 | 2.9 | |
| Follow up, in years | 823 | 9.3 ± 3.1 | |
| Development of breast cancer over complete follow-up period | |||
| No | 779 | 94.7 | |
| Yes, ipsilateral to clustered calcifications | 22 | 2.7 | |
| Yes, contralateral to clustered calcifications | 22 | 2.7 | |
a
Mastopathy = combination of (sclerosing) adenosis, epitheliosis, and or apocrine metaplasia.
b
PASH = pseudoangiomatous stromal hyperplasia.